drugset / Trial / NCT01790087
ANX-188 Thorough QT/QTc Study in Healthy Volunteers
RandomizedCrossoverTriple-blindBasic science
Summary
This study has been designed in compliance with the ICH-E14 guideline (2005) to evaluate the effect of ANX-188 at therapeutic and supratherapeutic concentrations on cardiac repolarization, specifically, Fridericia's QT-Interval (QTcF)
Timeline
- Start
- 2013-02
- Primary completion
- 2013-04
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANX-188 | Unknown | 30 mg/kg | Intravenous |
| Subject | ANX-188 | Unknown | 200 mg/kg | Intravenous |
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.